These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3509679)

  • 1. Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis.
    Godney EK; Arizpe HM; Gaunti CJ
    Viral Immunol; 1987-1988; 1(4):305-14. PubMed ID: 3509679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.
    Gauntt CJ; Arizpe HM; Higdon AL; Wood HJ; Bowers DF; Rozek MM; Crawley R
    J Immunol; 1995 Mar; 154(6):2983-95. PubMed ID: 7533190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of natural killer cells in coxsackievirus B3-induced murine myocarditis.
    Godeny EK; Gauntt CJ
    J Immunol; 1986 Sep; 137(5):1695-702. PubMed ID: 3018079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
    Gauntt CJ; Paque RE; Trousdale MD; Gudvangen RJ; Barr DT; Lipotich GJ; Nealon TJ; Duffey PS
    Infect Immun; 1983 Feb; 39(2):851-64. PubMed ID: 6299950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
    Yue Y; Xu W; Hu L; Jiang Z; Xiong S
    Virology; 2009 Apr; 386(2):438-47. PubMed ID: 19233446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine natural killer cells limit coxsackievirus B3 replication.
    Godeny EK; Gauntt CJ
    J Immunol; 1987 Aug; 139(3):913-8. PubMed ID: 3036947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levamisole exacerbates coxsackievirus B3-induced murine myocarditis.
    Gudvangen RJ; Duffey PS; Paque RE; Gauntt CJ
    Infect Immun; 1983 Sep; 41(3):1157-65. PubMed ID: 6309663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
    Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
    Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Coxsackievirus B3 neutralizing antibodies with pathological potential.
    Gauntt CJ; Arizpe HM; Higdon AL; Rozek MM; Crawley R; Cunningham MW
    Eur Heart J; 1991 Aug; 12 Suppl D():124-9. PubMed ID: 1717270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coxsackievirus-B3-induced myocarditis: virus receptor antibodies modulate myocarditis.
    Weller AH; Simpson K; Herzum M; Van Houten N; Huber SA
    J Immunol; 1989 Sep; 143(6):1843-50. PubMed ID: 2550544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immune responses in mice challenged with an amyocarditic variant of Coxsackievirus B3.
    Lutton CW; Gudvangen RJ; Nealon TJ; Paque RE; Gauntt CJ
    J Med Virol; 1985 Dec; 17(4):345-57. PubMed ID: 3001222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection.
    Jrad-Battikh N; Souii A; Oueslati L; Aouni M; Hober D; Gharbi J; Ben M'hadheb-Gharbi M
    Curr Microbiol; 2014 Apr; 68(4):503-9. PubMed ID: 24322405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
    Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
    Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis.
    Park JH; Kim DS; Cho YJ; Kim YJ; Jeong SY; Lee SM; Cho SJ; Yun CW; Jo I; Nam JH
    Vaccine; 2009 Mar; 27(13):1974-83. PubMed ID: 19168108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of murine coxsackievirus-induced myocarditis utilizing anti-idiotypes.
    Paque RE; Miller R
    Viral Immunol; 1987-1988; 1(3):207-24. PubMed ID: 3509677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxsackievirus-induced chronic myocarditis in murine models.
    Gauntt CJ; Tracy SM; Chapman N; Wood HJ; Kolbeck PC; Karaganis AG; Winfrey CL; Cunningham MW
    Eur Heart J; 1995 Dec; 16 Suppl O():56-8. PubMed ID: 8682103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
    Fan X; Yue Y; Xiong S
    Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of cell-mediated immunity against coxsackievirus B3-induced myocarditis in a primate model (Papio papio).
    Paque RE; Gauntt CJ; Nealon TJ
    Infect Immun; 1981 Jan; 31(1):470-9. PubMed ID: 6260666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice.
    Leipner C; Borchers M; Merkle I; Stelzner A
    J Hum Virol; 1999; 2(2):102-14. PubMed ID: 10225212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
    Fohlman J; Pauksen K; Morein B; Bjare U; Ilbäck NG; Friman G
    Scand J Infect Dis Suppl; 1993; 88():103-8. PubMed ID: 8390713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.